NEW YORK (GenomeWeb) – Paragon Genomics said today it has closed an $8 million Series A financing round.

According to Paragon CEO Tao Chen, the company plans to use the funds to develop next-generation sequencing assays in the oncology and precision medicine space, and expand its US commercial team. He added that the firm's CleanPlex 2.5-hour multiplex PCR target-enrichment workflow for Illumina NGS platforms has been adopted by more than 50 NGS labs globally, and Paragon is looking to expand into Europe, Asia, and South America through partnership and distributorship deals.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.

Sponsored by

This webinar will describe a protocol and proof-of-principle experiments for Cellular Indexing of Transcriptome and Epitopes by Sequencing (CITE-seq).

Sponsored by
Philips Genomics

This webinar will present an in-depth look at how Memorial Sloan Kettering Cancer Center has developed and implemented a next-generation sequencing panel for mutational tumor profiling of advanced cancer patients.

Sponsored by
Fabric Genomics

This webinar will discuss the critical role that software can play for clinical labs looking to establish comprehensive genomic testing programs. 

Sponsored by

This webinar will be a roundtable discussion on the adoption of a commercial gene panel for tumor profiling at several leading US cancer centers.